Patents by Inventor Tyler D. Ames

Tyler D. Ames has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • PHOSPHAPLATIN COMPOUNDS AS THERAPEUTIC AGENTS SELECTIVELY TARGETING HIGHLY GLYCOLYTIC TUMOR CELLS AND METHODS THEREOF
    Publication number: 20240009212
    Abstract: A cellular model with a highly glycolytic phenotype (L929dt cells) for study of phosphaplatin-based anticancer agents, in particular (R,R)-1,2-cyclohexanediamine-(pyrophosphato) platinum(II) (or “PT-112”), is disclosed. The expression of HIF-1? as a biomarker of glycolytic cells sensitive to PT-112, clinical applications of the biomarker, and methods thereof for diagnosis and treatment of patients with cancers are disclosed.
    Type: Application
    Filed: October 20, 2021
    Publication date: January 11, 2024
    Applicant: Promontory Therapeutics Inc.
    Inventors: Tyler D. Ames, Alberto Anel
  • Phosphaplatin liquid formulations
    Patent number: 11154529
    Abstract: Pharmaceutical compositions of phosphaplatin compounds, in particular buffered stable liquid formulations of pyrodach-2 ready for use in the treatment of various cancers, and methods of preparation are disclosed.
    Type: Grant
    Filed: April 5, 2017
    Date of Patent: October 26, 2021
    Assignee: Phosplatin Therapeutics Inc.
    Inventors: Wayne D. Luke, Tyler D. Ames